Pharmorage is the result of a strategic collaboration between the ASX listed Noxopharm Limited and Melbourne’s Hudson Institute of Medical Research, created to enhance mRNA vaccine technology and to discover and develop new treatments for a wide range of autoimmune and inflammatory diseases.
As a fully-owned subsidiary of Noxopharm, Pharmorage is focused on bringing to the healthcare industry novel new technologies that modulate inflammation at its source.
The technology is based on ultra-short oligonucleotides. These oligos are being applied to make mRNA vaccines safer by reducing vaccine-associated inflammatory side-effects, and in autoimmune diseases including systemic lupus erythematosus (SLE), psoriasis, type 1 diabetes, rheumatoid arthritis and multiple sclerosis.
Pharmorage and Hudson Institute have a close strategic partnership and are continuing to expand their family of patent applications, which are in various stages of examination. Pharmorage is licenced to commercialise any promising drug candidates generated through this work.
Pharmorage’s role as a subsidiary supports Noxopharm’s Sofra™ platform and gives the parent company strategic flexibility in a rapidly-evolving global market.